A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

BACKGROUND: Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study was designed to assess the efficacy and safety of anlotinib plus paclitaxel and cisplatin (TP) as first-line therapy for advanced ESCC. METHODS: In a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Wu, Tao, Hong, Yong-Gui, Guo, Yan-Zhen, Cheng, Yu-Feng, Ma, Yi-Jie, Bie, Liang-Yu, Cui, Dong-Hai, Gao, Xiao-Hui, Tan, Bing-Xu, Li, Bao-Sheng, Luo, Su-Xia, Wang, Jun-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733004/
https://www.ncbi.nlm.nih.gov/pubmed/36482345
http://dx.doi.org/10.1186/s12916-022-02649-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733004/
https://www.ncbi.nlm.nih.gov/pubmed/36482345
http://dx.doi.org/10.1186/s12916-022-02649-x

Ejemplares similares